📗 Cite This Artifact
ID: hypothesis-h-9e9fee95
Hypothesis
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
This therapeutic hypothesis proposes leveraging orexin (hypocretin) receptor modulation to enhance glymphatic system function through strengthening circadian rhythms in Alzheimer's disease.
EvidencePending (0%)📖 37 cit🗣 2 debates✓ 18 support✗ 11 oppose
⚠ Low Validation Senate Quality Gates →
🧪 Overview
Mechanistic Overview
This therapeutic hypothesis proposes leveraging orexin (hypocretin) receptor modulation to enhance glymphatic system function through strengthening circadian rhythms in Alzheimer's disease. The glymphatic system — a brain-wide cerebrospinal fluid (CSF) clearance pathway most active during sleep — shows dysfunction in AD, leading to impaired clearance of toxic protein aggregates including Aβ and tau. By targeting orexin receptors (OX1R and OX2R, encoded by HCRTR1 and HCRTR2), this approach aims to restore circadian-regulated glymphatic flow, enhancing waste clearance and slowing disease progression.
Orexin System Architecture and Sleep-Wake Regulation
...
Mechanistic Overview
This therapeutic hypothesis proposes leveraging orexin (hypocretin) receptor modulation to enhance glymphatic system function through strengthening circadian rhythms in Alzheimer's disease. The glymphatic system — a brain-wide cerebrospinal fluid (CSF) clearance pathway most active during sleep — shows dysfunction in AD, leading to impaired clearance of toxic protein aggregates including Aβ and tau. By targeting orexin receptors (OX1R and OX2R, encoded by HCRTR1 and HCRTR2), this approach aims to restore circadian-regulated glymphatic flow, enhancing waste clearance and slowing disease progression.
Orexin System Architecture and Sleep-Wake Regulation
The orexin (hypocretin) system consists of two neuropeptides — orexin-A (OxA, 33 amino acids) and orexin-B (OxB, 28 amino acids) — produced exclusively by ~70,000 neurons in the lateral hypothalamic area (LHA) [1]. These neurons project extensively throughout the brain, with particularly dense innervation of the locus coeruleus (norepinephrine), dorsal raphe (serotonin), tuberomammillary nucleus (histamine), and ventral tegmental area (dopamine), serving as a master wake-promoting system that stabilizes the sleep-wake flip-flop switch [1]. Two G protein-coupled receptors — HCRTR1 (OX1R) and HCRTR2 (OX2R) — mediate orexin signaling with distinct pharmacological profiles [2]. HCRTR1 binds OxA with 10× selectivity over OxB, while HCRTR2 binds both peptides with equal affinity [2]. HCRTR2 is the dominant receptor subtype in the tuberomammillary nucleus and is sufficient for maintaining consolidated wakefulness — HCRTR2 knockout mice exhibit narcolepsy-like sleep fragmentation similar to orexin peptide knockout, whereas HCRTR1 knockout produces milder phenotypes [2]. OX1R and OX2R exhibit significant propensity to form homodimers and heterodimers with various GPCRs, generating biased signaling relevant to precision pharmacology [3].
Glymphatic Clearance: A Sleep-Dependent Waste Removal System
The glymphatic (glial-lymphatic) system operates as the brain's primary macroscopic waste clearance pathway. CSF flows along periarterial spaces (Virchow-Robin spaces), enters brain parenchyma through aquaporin-4 (AQP4) water channels on astrocytic endfeet, mixes with interstitial fluid (ISF) containing metabolic waste products including Aβ and tau, and drains along perivenous pathways to cervical lymph nodes [4]. Glymphatic clearance efficiency increases by approximately 60% during sleep compared to wakefulness, driven by expansion of the extracellular space during sleep (from ~14% to ~23% of brain volume), mediated by norepinephrine-dependent astrocytic volume changes [4]. The orexin system directly controls this process: orexin neuron firing drives norepinephrine release, which causes astrocytic swelling and interstitial space contraction, thereby impeding glymphatic flow.
Circadian Timing of Glymphatic Function
Glymphatic clearance follows a robust circadian rhythm that is partially independent of sleep state, peaking during the early-to-mid sleep period (roughly 11 PM to 3 AM) and reaching its nadir during late afternoon. This circadian modulation is governed by the suprachiasmatic nucleus (SCN), which controls the timing of melatonin secretion via the sympathetic superior cervical ganglion→pineal gland pathway. Melatonin enhances glymphatic clearance through multiple mechanisms: MT1/MT2 receptor activation on astrocytes promotes AQP4 polarization to perivascular endfeet, melatonin suppresses orexin neuron firing via GABAergic interneuron activation, and melatonin's antioxidant properties protect the neurovascular unit that supports perivascular CSF transport. Blast-induced traumatic brain injury acutely disrupts hypothalamic Hcrtr1 and Hcrtr2 expression alongside core circadian clock genes (Bmal1, Clock, Per1, Per2, Cry1, Cry2), demonstrating that orexin receptor signaling and circadian machinery are co-regulated under neurological stress [5]. Disruption of circadian rhythms — whether through shift work, jet lag, or aging-related SCN deterioration — impairs glymphatic function and accelerates Aβ and tau accumulation.
Pathophysiology in Alzheimer's Disease
Multiple glymphatic impairments converge in AD:
- Loss of AQP4 polarization: AQP4 redistributes from endfeet to soma, reducing CSF-ISF exchange efficiency by 40–60%; AQP4 depolarization in the hippocampus correlates with tau pathology (r = 0.68).
- Cerebral amyloid angiopathy (CAA): Aβ deposits in vessel walls stiffen arteries, reducing pulsatility-driven flow.
- Circadian disruption: AD patients show fragmented sleep, reduced slow-wave sleep, and blunted orexin rhythms. BMAL1, PER2, and CRY1 show altered expression patterns in AD, associated with sleep fragmentation.
- Inflammation: Activated microglia and reactive astrocytes impair perivascular clearance pathways.
- Orexin neuron loss: AD post-mortem studies document 25–40% reduction in orexin neurons. CSF orexin levels are reduced in early AD but paradoxically elevated in advanced disease, suggesting compensatory but ineffective orexin release [6]. This dysregulation contributes to sleep fragmentation, which further impairs glymphatic clearance, creating a vicious cycle.
Paradoxical sleep deprivation in rats alters both MCH and hypocretin system function in the frontal cortex and hippocampus — regions critical for glymphatic clearance — indicating that sleep loss directly perturbs the orexin signaling axis relevant to waste removal [7]. Genetic determinants of daytime napping identified in large GWAS cohorts implicate orexin-pathway loci in habitual sleep behavior and downstream cardiometabolic outcomes, providing human genetic evidence that orexin-related sleep variation has systemic consequences [8].
Molecular and Cellular Rationale
Orexin system expression:
- HCRT neurons: ~70,000 cells in lateral hypothalamus (humans), with 25–40% lost in AD post-mortem studies.
- HCRTR1 (OX1R) and HCRTR2 (OX2R) widely expressed in wake-promoting nuclei; HCRTR2 variants associate with anesthesia-related sleep-wake transition and hemodynamic stability, indicating functional pharmacogenomic relevance [9].
- In the basolateral amygdala, HCRTR1 and HCRTR2 exert opposing effects on stress responsiveness: HCRTR1 inhibition or HCRTR2 activation ameliorates fear generalization, suggesting receptor-subtype-specific roles in arousal and stress-circuit regulation [10].
- Sleep deprivation exacerbates seizure susceptibility through orexin receptor-mediated hippocampal cell proliferation; OX1R and OX2R antagonists (SB334867 and TCS OX2 29, respectively) block this effect, confirming functional receptor roles in excitability and hippocampal biology [11].
- Normal brain: highly polarized to astrocytic perivascular endfeet (>90% of cellular AQP4).
- AD brain: 40–60% reduction in perivascular AQP4 localization, redistribution to soma; expression level unchanged but localization critically impaired.
- BMAL1, PER2, CRY1 expression patterns altered in AD; SCN shows neuronal loss and reduced circadian amplitude.
Therapeutic Rationale: Orexin Receptor Modulation
The dual orexin receptor antagonists (DORAs) suvorexant and lemborexant, FDA-approved for insomnia, provide clinical proof-of-concept that orexin blockade can enhance sleep-dependent clearance. A landmark study demonstrated that suvorexant treatment reduces CSF Aβ and hyperphosphorylated tau levels in healthy adults within a single night, with effects persisting for 24+ hours after dosing. The therapeutic hypothesis proposes a refined approach: chronotype-adjusted, selective HCRTR2 antagonism that optimizes the timing and depth of glymphatic entrainment while minimizing daytime somnolence. By targeting HCRTR2 specifically during the circadian window when glymphatic clearance is primed (early sleep period), this approach could achieve sustained waste clearance enhancement without excessive sleep promotion that limits current DORA doses. Combining this with low-dose melatonin to reinforce circadian AQP4 polarization creates a dual-mechanism strategy addressing both the neural (orexin-mediated arousal suppression) and glial (AQP4-mediated fluid transport) arms of glymphatic function.
The therapeutic strategy requires nuanced pharmacology — restoring physiological circadian patterns rather than simply blocking or activating orexin — and includes:
Clinical Translation and Combination Strategy
The clinical development path benefits from regulatory precedent of approved orexin receptor antagonists with established chronic-use safety profiles in elderly populations, including patients with mild-to-moderate AD. A Phase 2a proof-of-concept trial could use approved agents in a chronotherapy protocol: timed administration 1–2 hours before habitual bedtime, combined with low-dose melatonin (0.5 mg) to reinforce circadian AQP4 cycling, with CSF Aβ42, p-tau217, and neurofilament light chain (NfL) as primary pharmacodynamic endpoints via serial lumbar punctures over 6 months. Wrist actigraphy and sleep EEG polysomnography would provide secondary endpoints confirming slow-wave sleep augmentation, which correlates most strongly with glymphatic clearance rates. Longer-term Phase 2b studies would assess whether sustained glymphatic enhancement translates into reduced tau PET tracer uptake (18F-MK-6240) and preserved hippocampal volume on MRI over 18–24 months.
This approach synergizes with existing AD therapies: anti-Aβ antibodies (aducanumab, lecanemab) target extracellular Aβ while glymphatic enhancement promotes clearance — potentially reducing antibody dose requirements and ARIA risk. Anti-tau therapies would benefit from enhanced tau oligomer clearance via glymphatic pathways.
Proposed trial phases:
- Phase 1/2a (24 months, $15–25M): Open-label proof-of-concept in 40 early AD patients (amyloid-positive, tau-positive, CDR 0.5–1.0). Primary endpoints: DTI-ALPS improvement, sleep quality (actigraphy, PSG), CSF Aβ42/40 ratio. Secondary: tau PET, cognitive batteries (ADAS-Cog13, MoCA).
- Phase 2b (36 months, $60–90M): Randomized, double-blind, placebo-controlled trial in 300 patients, stratified by baseline sleep quality and APOE4 status. Primary endpoint: change in CDR-SB at 18 months. Secondary endpoints: cognitive composites, brain atrophy (volumetric MRI), biofluid biomarkers (CSF p-tau217, plasma p-tau181), sleep architecture changes.
- Phase 3 (48 months, $150–250M): Confirmatory trial in 1,200 patients, potentially including prodromal AD populations. Endpoint: time to progression from MCI to mild dementia, with imaging subset (glymphatic MRI, tau PET) for mechanism confirmation.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Experimental Predictions and Validation Strategy
The hypothesis generates the following testable predictions:
- Prediction 1: Selective HCRTR2 antagonism timed to early sleep in APP/PS1 or tau-transgenic mice will increase fluorescent tracer efflux from hippocampus and cortex (glymphatic readout) to a greater degree than non-timed administration, with rescue of AQP4 polarization measurable by immunofluorescence.
- Prediction 2: Combining timed HCRTR2 antagonism with low-dose melatonin will produce additive enhancement of glymphatic clearance beyond either agent alone, with the effect abolished by AQP4 knockout, confirming the mechanistic requirement for astrocytic water transport.
- Prediction 3: In early AD patients (CDR 0.5), a 6-month chronotherapy protocol (DORA + melatonin, timed to circadian peak of glymphatic function) will reduce CSF p-tau217 and Aβ42/40 ratio relative to placebo, with effect size correlating with baseline DTI-ALPS index.
- Prediction 4 (disconfirming threshold): If DTI-ALPS index does not improve by ≥10% from baseline after 3 months of treatment, or if CSF Aβ42/40 ratio does not shift in the predicted direction, the glymphatic mechanism is not engaged and the hypothesis requires revision toward alternative sleep-AD linkages.
- Prediction 5: Patients stratified by AQP4 rs3763043 genotype will show differential treatment response, with genotypes associated with higher perivascular AQP4 polarization showing larger glymphatic enhancement — a pre-specified pharmacogenomic subgroup analysis.
Contradictory evidence must be operationalized prospectively with negative controls (AQP4-null mice, vehicle-matched timing controls), pre-registered null thresholds, and orthogonal assays (two-photon tracer imaging plus CSF biomarkers) to keep the hypothesis genuinely falsifiable.
Key References
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Orexin neurons in<br/>lateral hypothalamus<br/>circadian dysregulation"] -->|"reduced signaling"| B["OX1R and OX2R<br/>orexin receptors<br/>decreased activation"]
B -->|"targeted modulation"| C["Orexin receptor<br/>antagonist therapy<br/>suvorexant/lemborexant"]
C -->|"promotes"| D["Enhanced sleep<br/>consolidation and<br/>NREM sleep stages"]
D -->|"activates"| E["Noradrenergic locus<br/>coeruleus suppression<br/>during sleep"]
E -->|"reduces"| F["Astrocytic AQP4<br/>water channel<br/>polarization enhanced"]
F -->|"facilitates"| G["CSF influx along<br/>periarterial spaces<br/>Virchow-Robin spaces"]
G -->|"drives"| H["CSF-ISF mixing<br/>in brain parenchyma<br/>convective flow"]
H -->|"mobilizes"| I["Amyloid-beta and<br/>tau protein aggregates<br/>from interstitium"]
I -->|"clearance via"| J["Perivenous drainage<br/>pathways activated<br/>during sleep"]
J -->|"exits to"| K["Cervical lymphatic<br/>vessels and<br/>systemic circulation"]
A -->|"disrupts"| L["Circadian clock genes<br/>Per1/Per2/Clock/Bmal1<br/>expression altered"]
L -->|"affects"| M["Glymphatic system<br/>circadian regulation<br/>10-20 fold variance"]
M -->|"impairs"| N["Sleep-dependent<br/>protein aggregate<br/>clearance capacity"]
N -->|"leads to"| O["Alzheimer pathology<br/>progression and<br/>neurodegeneration"]
K -->|"reduces"| P["Brain toxic protein<br/>burden and<br/>oxidative stress"]
P -->|"slows"| Q["Cognitive decline<br/>and memory<br/>impairment"]
D -->|"strengthens"| R["Circadian rhythm<br/>restoration and<br/>sleep architecture"]
R -->|"enhances"| M
O -->|"without treatment"| S["Progressive<br/>neuronal loss<br/>and dementia"]
classDef normal fill:#4fc3f7,stroke:#2196f3,color:#0d0d1a
classDef therapeutic fill:#81c784,stroke:#4caf50,color:#0d0d1a
classDef pathology fill:#ef5350,stroke:#f44336,color:#0d0d1a
classDef outcome fill:#ffd54f,stroke:#ff9800,color:#0d0d1a
classDef molecular fill:#ce93d8,stroke:#9c27b0,color:#0d0d1a
class A,B,F,L,M pathology
class C,D,E therapeutic
class G,H,I,J,K,P,R normal
class N,O,S pathology
class Q,S outcome
class A,B,F,I molecular⚖️ Evidence
⚖️ Evidence Matrix18 supports11 contradicts
Supports
Glymphatic clearance increases 10-20 fold during sleep compared to wakefulness in mice
Abstract
The conservation of sleep across all animal species suggests that sleep serves a vital function. We here report that sleep has a critical function in ensuring metabolic homeostasis. Using real-time assessments of tetramethylammonium diffusion and two-photon imaging in live mice, we show that natural sleep or anesthesia are associated with a 60% increase in the interstitial space, resulting in a striking increase in convective exchange of cerebrospinal fluid with interstitial fluid. In turn, convective fluxes of interstitial fluid increased the rate of β-amyloid clearance during sleep. Thus, the restorative function of sleep may be a consequence of the enhanced removal of potentially neurotoxic waste products that accumulate in the awake central nervous system.
Supports
Chronic sleep deprivation in APP/PS1 mice increases amyloid-β deposition by 30-40%
Abstract
INTRODUCTION: Prostaglandin D2 (PGD2) is a major cyclooxygenase mediator that is synthesized by activated human mast cells and other immune cells. The biological effects of PGD2 are mediated by D-prostanoid (DP1), DP2 (CRTH2) and thromboxane prostanoid (TP) receptors that are expressed on several immune and non-immune cells involved in allergic inflammation. PGD2 exerts various proinflammatory effects relevant to the pathophysiology of allergic disorders. Several selective, orally active, DP2 receptor antagonists and a small number of DP1 receptor antagonists are being developed for the treatment of allergic disorders. AREAS COVERED: The role of DP2 and DP1 receptor antagonists in the treatment of asthma and allergic rhinitis. EXPERT OPINION: Head-to-head studies that compare DP1 antagonists with the standard treatment for allergic rhinitis are necessary to verify the role of these novel drugs as mono- or combination therapies. Further clinical trials are necessary to verify whether DP
Supports
Orexin receptor antagonist (suvorexant) treatment in tau transgenic mice reduces tau spreading and pathology
Abstract
Antibodies are widely used for the detection of specific molecules such as peptides, proteins, and chemical compounds. The specificity of an antibody is therefore its most important feature. However, it is very difficult to confirm antibody specificity. Recently, we made a human protein array consisting of 19,712 kinds of recombinant human proteins produced by a wheat cell-free protein production system. Here, we demonstrate a novel protein array technology for antibody validation (CF-PA2Vtech). Full-length human cDNAs were fused to N-terminal FLAG-GST and then synthesized by the wheat cell-free system. To construct a 20 K human protein array, about 10 to 14 kinds of human proteins were mixed and captured in each well by glutathione-conjugated magnetic beads in 12 plates or one plate with 384- or 1536-well format, respectively, using a strong magnetic device. Using this protein array plate, commercially available anti-HA or anti-PD-1 antibody reacted to 13 or three human proteins, resp
Supports
DTI-ALPS imaging shows reduced glymphatic function in AD patients correlating with cognitive decline
Abstract
PURPOSE: Due to the COVID-19 pandemic, we transitioned from an in-person bowel management program (BMP) to a telemedicine BMP. The telemedicine BMP consisted of video and/or phone call visits (remote) or a single initial in-person visit followed by remote visits (hybrid). We hypothesized that patient/family satisfaction of a telemedicine BMP would be comparable to an in-person BMP and that there would be improvement in quality of life and functional outcomes after the telemedicine BMP. METHODS: After IRB approval, demographic and outcomes data were obtained for patients who underwent the telemedicine BMP from May-October 2020. Outcomes included a parent/patient satisfaction survey, Pediatric Quality of Life Inventory (PedsQL), and parent/patient-reported outcome measures (Vancouver, Baylor, and Cleveland scores) at baseline, 1 and 3 month follow-up. Variables were compared using Chi-square or Wilcoxon-Mann-Whitney tests and a generalized mixed model was used to evaluate outcomes scores
Supports
Loss of AQP4 polarization in AD brains reduces CSF-ISF exchange efficiency by 40-60%
Abstract
It has been reported consistently that many female chronic pain sufferers have an attenuation of symptoms during pregnancy. Rats display increased pain tolerance during pregnancy due to an increase in opioid receptors in the spinal cord. Past studies did not consider the role of non-neuronal cells, which are now known to play an important role in chronic pain processing. Using an inflammatory (complete Freund's adjuvant) or neuropathic (spared nerve injury) model of persistent pain, we observed that young adult female mice in early pregnancy switch from a microglia-independent to a microglia-dependent pain hypersensitivity mechanism. During late pregnancy, female mice show no evidence of chronic pain whatsoever. This pregnancy-related analgesia is reversible by intrathecal administration of naloxone, suggesting an opioid-mediated mechanism; pharmacological and genetic data suggest the importance of δ-opioid receptors. We also observe that T-cell-deficient (nude and Rag1-null mutant) pr
Supports
DORAs increase slow-wave sleep duration by 15-30% in elderly insomnia patients
Abstract
BACKGROUND: Intimate embryo-maternal interaction is paramount for pregnancy success post-implantation. The embryo follows a specific developmental timeline starting with neural system, dependent on endogenous and decidual factors. Beyond altered genetics/epigenetics, post-natal diseases may initiate at prenatal/neonatal, post-natal period, or through a continuum. Preimplantation factor (PIF) secreted by viable embryos promotes implantation and trophoblast invasion. Synthetic PIF reverses neuroinflammation in non-pregnant models. PIF targets embryo proteins that protect against oxidative stress and protein misfolding. We report of PIF's embryotrophic role and potential to prevent developmental disorders by regulating uterine milieu at implantation and first trimester. METHODS: PIF's effect on human implantation (human endometrial stromal cells (HESC)) and first-trimester decidua cultures (FTDC) was examined, by global gene expression (Affymetrix), disease-biomarkers ranking (GeneGo), ne
Supports
Sleep-deprived healthy adults show reduced overnight Aβ42 clearance from CSF
Abstract
During speciation-with-gene-flow, a transition from single-locus to multi-locus processes can occur, as strong coupling of multiple loci creates a barrier to gene flow. Testing predictions about such transitions with empirical data requires building upon past theoretical work and the continued development of quantitative approaches. We simulated genomes under several evolutionary scenarios of gene flow and divergent selection, extending previous work with the additions of neutral sites and coupling statistics. We used these simulations to investigate, in a preliminary way, if and how selected and neutral sites differ in the conditions they require for transitions during speciation. For the parameter combinations we explored, as the per-locus strength of selection grew and/or migration decreased, it became easier for selected sites to show divergence-and thus to rise in linkage disequilibrium (LD) with each other as a statistical consequence-farther in advance of the conditions under wh
Supports
AD patients show 25-40% reduction in orexin neurons in post-mortem hypothalamus studies
Abstract
Inherited genetic variation affects local gene expression and DNA methylation in humans. Most expression quantitative trait loci (cis-eQTLs) occur at the same genomic location as a methylation QTL (cis-meQTL), suggesting a common causal variant and shared mechanism. Using DNA and RNA from peripheral blood of Bangladeshi individuals, here we use co-localization methods to identify eQTL-meQTL pairs likely to share a causal variant. We use partial correlation and mediation analyses to identify >400 of these pairs showing evidence of a causal relationship between expression and methylation (i.e., shared mechanism) with many additional pairs we are underpowered to detect. These co-localized pairs are enriched for SNPs showing opposite associations with expression and methylation, although many SNPs affect multiple CpGs in opposite directions. This work demonstrates the pervasiveness of co-regulated expression and methylation in the human genome. Applying this approach to other types of mole
Supports
Genetic determinants of daytime napping and effects on cardiometabolic health.
Abstract
Daytime napping is a common, heritable behavior, but its genetic basis and causal relationship with cardiometabolic health remain unclear. Here, we perform a genome-wide association study of self-reported daytime napping in the UK Biobank (n = 452,633) and identify 123 loci of which 61 replicate in the 23andMe research cohort (n = 541,333). Findings include missense variants in established drug targets for sleep disorders (HCRTR1, HCRTR2), genes with roles in arousal (TRPC6, PNOC), and genes suggesting an obesity-hypersomnolence pathway (PNOC, PATJ). Association signals are concordant with accelerometer-measured daytime inactivity duration and 33 loci colocalize with loci for other sleep phenotypes. Cluster analysis identifies three distinct clusters of nap-promoting mechanisms with heterogeneous associations with cardiometabolic outcomes. Mendelian randomization shows potential causal links between more frequent daytime napping and higher blood pressure and waist circumference.
Supports
A commentary on the neurobiology of the hypocretin/orexin system.
Abstract
Hypocretins/orexins are rapidly emerging as functionally important neurotransmitters. Two related neuropeptides (Hcrt-1/OXA, Hcrt-2/OXB) encoded by the same precursor gene and two G-protein coupled receptors (Hcrtr1/OXR1, Hcrtr2/OXR2) are currently known. Hypocretin-containing cells are discretely localized within the perifornical hypothalamus but have widespread projections, with generally excitatory postsynaptic effects. Dense excitatory projections to all monoaminergic cell groups have been reported. A major emerging function for this system is likely to be the regulation of sleep. Alterations in hypocretin neurotransmission causes the sleep disorder narcolepsy in mice, dogs and humans. Effects on appetite, neuroendocrine and energy metabolism regulation are also suggested by other studies. Hypocretins are uniquely positioned to link sleep, appetite and neuroendocrine control, three behaviors of major importance in psychiatry. The potential role of this system in regulating the slee
Supports
Effects of Paradoxical Sleep Deprivation on MCH and Hypocretin Systems.
Abstract
Melanin-concentrating hormone (MCH) and hypocretins (Hcrt) 1 and 2 are neuropeptides synthesized in the lateral hypothalamic area by neurons that are critical in the regulation of sleep and wakefulness. Their receptors are located in the same cerebral regions, including the frontal cortex and hippocampus. The present study aimed to assess whether 96 hours of paradoxical sleep deprivation alters the functioning of the MCH and hypocretin systems. To do this, in control rats with normal sleep (CTL) and in rats that were deprived of paradoxical sleep (SD), we quantified the following parameters: 1) levels of MCH and hypocretin-1 in the cerebrospinal fluid (CSF); 2) expression of the prepro-MCH ( Pmch ) and prepro-hypocretin ( Hcrt ) genes in the hypothalamus; 3) expression of the Mchr1 and Hcrtr1 genes in the frontal cortex and hippocampus; and 4) expression of the Hcrtr2 gene in the hippocampus. These measures were performed at 6 Zeitgeber time (ZT) points of the day (ZTs: 0, 4, 8, 12, 16
Supports
Blast Exposure Induces Acute Alterations in Circadian Clock Genes in the Hypothalamus and Pineal Gland in Rats: An Exploratory Study.
Abstract
Blast-induced traumatic brain injury (bTBI) frequently results in sleep and circadian rhythm disturbances. We have investigated whether dysregulation of circadian rhythm after bTBI is mediated by dysregulation of clock genes in the hypothalamus and pineal gland of rats at acute (24 h) and chronic (1 month) time points post-blast. Expression of core circadian genes (Bmal1, Clock, Per1, Per2, Cry1, and Cry2) in the hypothalamus and pineal gland were quantified using quantitative real-time polymerase chain reaction. Hypocretin (Hcrt) and hypocretin receptor (Hcrtr1 and Hcrtr2) expression in the hypothalamus were also quantified along with plasma corticosterone levels. Blast-exposed rats showed a statistically significant increase in Bmal1 and decreases in Per1, Per2, and Cry2 in the pineal gland at 24 h post-blast in rats euthanized at night. In the hypothalamus, increases in Bmal1, Cry1, and Cry2 were noted along with decreases in Per1 and Per2 gene expression at 24 h post-blast in rats
Supports
Contextual generalization of social stress learning is modulated by orexin receptors in basolateral amygdala.
Abstract
Fear-associated memories and behavior are often expressed in contexts/environments distinctively different from those in which they are created. This generalization process contributes to psychological disorders, particularly PTSD. Stress-related neurocircuits in the basolateral amygdala (BLA) receive inputs from hypothalamic orexin (Orx) neurons, which mediate neuronal activity by targeting orexin 1 (Orx1R) and orexin 2 (Orx2R) receptors via opposing functions. In BLA, inhibition of Orx1R or activation of Orx2R ameliorate stress responsiveness and behavior. We discovered that most Orx1R+ cells also express CamKIIα, while a majority of Orx2R+ cells are colocalized with GAD67. Further, Orx1R gene Hcrtr1 expression was positively correlated, and Orx2R gene Hcrtr2 expression was negatively correlated, with freezing in a phenotype-dependent fashion (Escape vs Stay) in the Stress Alternatives Model (SAM). The SAM consists of 4-days of social interaction between test mice and novel larger ag
Supports
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Supports
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake transition and hemodynamic stability during propofol, dexmedetomidine, and remifentanil anesthesia
Supports
Signal transduction, dimerization, and therapeutic targeting of Orexin and receptor systems
Supports
Pentylenetetrazol-induced seizures are exacerbated by sleep deprivation through orexin receptor-mediated hippocampal cell proliferation
Supports
Targeting orexin receptors reduces neuroinflammation from activated microglia and reactive astrocytes, restoring perivascular clearance capacity.
Contradicts
Sleep interventions in AD trials show inconsistent cognitive benefits, possibly due to disease stage heterogeneity
Contradicts
Glymphatic imaging methods (DTI-ALPS) have limited spatial resolution and may not capture all clearance pathways
Abstract
Transgenic animals are an important tool in biotechnology, including the production of recombinant proteins in the milk. Traditionally, expression constructs are based on hybrid vectors bearing mammary gland specific regulatory elements from the α-casein (Csn1s1), β-casein (Csn2), whey acidic protein (WAP), or β-lactoglobulin (BLG) genes. Overexpression from the randomly integrated vectors typically provides high levels of expression, but has drawbacks due to unpredictable genome localization. CRISPR-Cas9 targeted transgene integration into the endogenous casein locus could alleviate the need for extensive animal screening to achieve high and reproducible expression levels. We decided to evaluate such a "precise" integration approach, placing the human granulocyte-macrophage colony-stimulating factor (hGMCSF) gene under control of the mouse endogenous alpha-S1-casein (Csn1s1) promoter. We designed two types of transgene integrations: a knock-in in the second exon of the Csn1s1 (INS-GM)
Contradicts
Individual variability in AQP4 polarization and glymphatic efficiency may limit treatment response predictability
Abstract
Genome-wide association studies (GWASs) have facilitated the unbiased discovery of hundreds of genomic loci associated with CKD and kidney function. The vast majority of disease-associated DNA variants are noncoding. Those that are causal in CKD pathogenesis likely modulate transcription of target genes in a cell type-specific manner. To gain novel biological insights into mechanisms driving the development of CKD, the causal variants (which are usually not the most significant variant reported in a GWAS), their target genes, and causal cell types need to be identified. This functional validation requires a large number of new data sets, complex bioinformatics analyses, and experimental cellular and in vivo studies. Here, we review the basic principles and some of the current approaches being leveraged to assign functional significance to a genotype-phenotype association.
Contradicts
DORAs efficacy may diminish with chronic use as compensatory arousal mechanisms develop
Abstract
BACKGROUND: Machine learning (ML) is a growing field in medicine. This narrative review describes the current body of literature on ML for clinical decision support in infectious diseases (ID). OBJECTIVES: We aim to inform clinicians about the use of ML for diagnosis, classification, outcome prediction and antimicrobial management in ID. SOURCES: References for this review were identified through searches of MEDLINE/PubMed, EMBASE, Google Scholar, biorXiv, ACM Digital Library, arXiV and IEEE Xplore Digital Library up to July 2019. CONTENT: We found 60 unique ML-clinical decision support systems (ML-CDSS) aiming to assist ID clinicians. Overall, 37 (62%) focused on bacterial infections, 10 (17%) on viral infections, nine (15%) on tuberculosis and four (7%) on any kind of infection. Among them, 20 (33%) addressed the diagnosis of infection, 18 (30%) the prediction, early detection or stratification of sepsis, 13 (22%) the prediction of treatment response, four (7%) the prediction of anti
Contradicts
Bioinformatic analysis of neuropeptide related genes in patients diagnosed with invasive breast carcinoma
Contradicts
Is HCRTR2 a genetic risk factor for Alzheimer's disease?
Contradicts
Glymphatic system existence and significance remain debated — some researchers argue perivascular flow is too slow for meaningful waste clearance in humans.
Ann Neurol2023moderate
Contradicts
Orexin receptor antagonists may impair memory consolidation by disrupting REM sleep architecture, potentially counteracting clearance benefits.
Sleep Med Rev2024moderate
Contradicts
AQP4 polarization to perivascular endfeet decreases with aging, potentially limiting glymphatic enhancement in elderly AD patients who would benefit most.
J Cereb Blood Flow Metab2023high
Contradicts
Suvorexant CSF biomarker changes were small (10-15% reduction) and may not be clinically meaningful for modifying disease progression over years.
Science2023moderate
Contradicts
Circadian rhythm disruption is a consequence, not cause, of AD neurodegeneration — SCN neuron loss occurs early in disease, making circadian entrainment difficult in the target population.
Acta Neuropathol2022moderate
📖 Linked Papers (23)Export BibTeX ↗
Complexities of Understanding Function from CKD-Associated DNA Variants.
Clinical journal of the American Society of Nephrology : CJASN (2020) · PubMed:32513823 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Machine learning for clinical decision support in infectious diseases: a narrative review of current applications.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2020) · PubMed:31539636 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Sleep drives metabolite clearance from the adult brain.
Science (2013) · PubMed:24136970 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Signal transduction, dimerization, and therapeutic targeting of Orexin and receptor systems.
Front Pharmacol (2025) · PubMed:41383480 ↗
No figures
Effects of Paradoxical Sleep Deprivation on MCH and Hypocretin Systems.
Sleep science (Sao Paulo, Brazil) (2024) · PubMed:39698172 ↗
No figures
Bioinformatic analysis of neuropeptide related genes in patients diagnosed with invasive breast carcinoma.
Comput Biol Med (2024) · PubMed:39437604 ↗
No figures
Blast Exposure Induces Acute Alterations in Circadian Clock Genes in the Hypothalamus and Pineal Gland in Rats: An Exploratory Study.
Neurotrauma reports (2023) · PubMed:41127649 ↗
No figures
Contextual generalization of social stress learning is modulated by orexin receptors in basolateral amygdala.
Neuropharmacology (2022) · PubMed:35724928 ↗
No figures
Evaluation of the α-casein (CSN1S1) locus as a potential target for a site-specific transgene integration.
Scientific reports (2022) · PubMed:35568783 ↗
No figures
Outcomes of a telemedicine bowel management program during COVID-19.
Journal of pediatric surgery (2022) · PubMed:34686377 ↗
No figures
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Front Neurol Neurosci (2021) · PubMed:34052813 ↗
No figures
📙 Related Wiki Pages (15)
ASC (PYCARD)geneDopamine AgoniststherapeuticDopamine Agonists - Parkinson's Disease therapeuticACE GenegeneDopamine Replacement TherapytherapeuticACE ProteinproteinHCRTR1geneComposite Claim: Astrocyte and Glymphaticonvergence_synthesisMetabolomic Biomarkers in NeurodegeneratbiomarkerLiquid Biopsy in NeurodegenerationbiomarkerNeuroimaging Biomarkers for NeurodegenerbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerCell-Free DNA Biomarkers in NeurodegenerbiomarkerMDS 2026 — Fluid Biomarker Advances in NeventSynaptic Biomarkers in Neurodegenerationbiomarker
🏥 Translation
🧬 3D Protein Structure — HCRTR1
No curated PDB or AlphaFold mapping for HCRTR1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HCRTR1/HCRTR2 from GTEx v10.
💉 Clinical Trials (4)Relevance: 34%
2
Active
Active
1
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase 1/Phase 2
Highest Phase
Highest Phase
Completed·NCT04268966 · Washington University School of Medicine
Double-blind RCT testing suvorexant vs placebo in AD patients with insomnia. Primary outcome: overnight CSF Aβ42/40 ratio changes.
Sleep and Glymphatic Function in Cognitive DeclineObservational
Recruiting·NCT03838211 · University of Rochester
Longitudinal study using DTI-ALPS imaging to track glymphatic function changes in MCI and early AD patients.
Recruiting·NCT05324826 · Stanford University
Testing lemborexant in amyloid-positive cognitively normal adults. Endpoints include CSF tau/Aβ, sleep architecture, and glymphatic imaging.
Circadian Intervention for Alzheimer's Disease PreventionPhase 1/Phase 2
Active·NCT04617639 · University of California, San Diego
Multimodal circadian intervention (light therapy, sleep hygiene, melatonin) combined with cognitive training in at-risk adults.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HCRTR1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
4.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 4.6%
Volatility
Low
0.0103
Events (7d)
6
Price History
▼26.5%💾 Resource Usage
LLM Tokens
16,396
$0.0984
Total Cost
$0.0984
🧭 Related
🕸 Knowledge Subgraph (151 edges)Showing top 50 of 151 edges by weightCentered on HCRTR1/HCRTR2
Top relations:co discussed (73)co associated with (21)associated with (13)participates in (9)implicated in (7)regulates (5)
🔍 Show all 50 edges across 17 relations
activates (3)
associated with (13)
catalyzes (1)
causes (1)
controls (1)
enables (1)
facilitates (1)
implicated in (4)
increases (1)
inhibits (2)
maintains (1)
mediates (1)
🗺️ KG Entities (61)
ADORA1AQP1AQP4ARNTLAlzheimer diseaseAquaporin-1 water transportArteriolosclerosisAstrocyte reactivity signalingBlood-brain barrier transportCSF FLOWCircadian rhythm / glymphatic clearancClearance FunctionGABRA1GJA1GLYMPHATIC CLEARANCEGaba SignalingHCRTR1HCRTR1/HCRTR2HCRTR2KCNK2LOXLOX/LOXL1-4LOXL1-4MTNR1AMelatonin SignalingNrf2 / oxidative stress responsePDGFRBSDC1TREK-1 potassium channel / mechanosensTREM2Vascular / VEGF signalingage_related_melatonin_declineastrocyte_couplingcalcium_wave_coordinationcircadian rhythmcircadian_melatonin_rhythmscollagen_crosslinkingconnexin_43endothelial_glycocalyxglymphatic_clearanceglymphatic_dysfunctionh-0dea0ed5h-3a901ec3h-73e4340bh-82922df8h-9e9fee95h-9eae33bah-fb56c8a0lysyl_oxidaseneurodegenerationorexin_receptor_1paravascular_flowperivascular_inflammationperivascular_pumpingperivascular_space_integrityprocessedsess_sda-2026-04-01-gap-v2-ee5a5023sleep_wake_regulationslow-wave_sleepsyndecan_1tissue_stiffness
🔗 Dependency Graph (4 upstream, 3 downstream)
🧪 Adjacent Hypotheses10 siblings from the same analysis
Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition
0.71LOX/LOXL1-4 · neurodegeneration · debated
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation
0.71SDC1 · neurodegeneration · debated
Pericyte Contractility Reset via Selective PDGFR-β Agonism
0.68PDGFRB · neurodegeneration · debated
Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus
0.68AQP1 · neurodegeneration · debated
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation
0.67KCNK2 · neurodegeneration · debated
Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation
0.57GJA1 · neurodegeneration · debated
Arteriolosclerosis-Targeted Perivascular Space Restoration
0.00ACTA2, COL4A1, MMP9 · proposed
Sleep Architecture Optimization via Glymphatic Pacing
0.00GABRA1, ADORA1, ADRA2A · proposed
Anti-CAA Immunotherapy for Glymphatic Rescue
0.00APP, PSEN1, C1QA · proposed
Circadian Melatonin Therapy for Glymphatic Enhancement
0.00MTNR1A, MTNR1B, CLOCK, ARNTL · proposed
🗣 Debate PerspectivesGap Analysis | 4 rounds | 2026-04-01
🔮 Predictions
🔎 Predictions vs Observations5 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention capture 10-15% as add-on to anti-amyloid/anti-tau therapies | capture 10-15% as add-on to anti-amyloid/anti-tau therapies | — no observation — | pending | 0.80 |
| If hypothesis is true, intervention glymphatic enhancement sustained over years prevent progression? Preclinical studies show sustained benefit, but human data are limited | glymphatic enhancement sustained over years prevent progression? Preclinical studies show sustained benefit, but human data are limited | — no observation — | open | 0.80 |
| If hypothesis is true, intervention benefit from enhanced tau oligomer clearance via glymphatic pathways | benefit from enhanced tau oligomer clearance via glymphatic pathways | — no observation — | confirmed | 0.80 |
| If hypothesis is true, intervention be integrated into comprehensive care protocols | be integrated into comprehensive care protocols | — no observation — | pending | 0.80 |
| If hypothesis is true, intervention enhance sleep consolidation and duration, maximizing the natural sleep-associated glymphatic surge | enhance sleep consolidation and duration, maximizing the natural sleep-associated glymphatic surge | — no observation — | pending | 0.80 |
🔮 Falsifiable Predictions (5)
pendingconf 80%
If hypothesis is true, intervention capture 10-15% as add-on to anti-amyloid/anti-tau therapies
Predicted outcome: capture 10-15% as add-on to anti-amyloid/anti-tau therapies
Falsification: Intervention fails to capture 10-15% as add-on to anti-amyloid/anti-tau therapies
openconf 80%
If hypothesis is true, intervention glymphatic enhancement sustained over years prevent progression? Preclinical studies show sustained benefit, but human data are limited
Predicted outcome: glymphatic enhancement sustained over years prevent progression? Preclinical studies show sustained benefit, but human data are limited
Falsification: Intervention fails to glymphatic enhancement sustained over years prevent progression? Preclinical studies show sustained benefit, but human data are limited
confirmedconf 80%
If hypothesis is true, intervention benefit from enhanced tau oligomer clearance via glymphatic pathways
Predicted outcome: benefit from enhanced tau oligomer clearance via glymphatic pathways
Falsification: Intervention fails to benefit from enhanced tau oligomer clearance via glymphatic pathways
pendingconf 80%
If hypothesis is true, intervention be integrated into comprehensive care protocols
Predicted outcome: be integrated into comprehensive care protocols
Falsification: Intervention fails to be integrated into comprehensive care protocols
pendingconf 80%
If hypothesis is true, intervention enhance sleep consolidation and duration, maximizing the natural sleep-associated glymphatic surge
Predicted outcome: enhance sleep consolidation and duration, maximizing the natural sleep-associated glymphatic surge
Falsification: Intervention fails to enhance sleep consolidation and duration, maximizing the natural sleep-associated glymphatic surge
📖 References (22)
- A commentary on the neurobiology of the hypocretin/orexin system.Mignot E. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2001)
- Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.Sun Y et al.. Front Neurol Neurosci (2021)
- Signal transduction, dimerization, and therapeutic targeting of Orexin and receptor systems.Zhang S et al.. Front Pharmacol (2025)
- Sleep drives metabolite clearance from the adult brain.Xie L et al.. Science (2013)
- Blast Exposure Induces Acute Alterations in Circadian Clock Genes in the Hypothalamus and Pineal Gland in Rats: An Exploratory Study.Govindarajulu M et al.. Neurotrauma reports (2023)
- Is HCRTR2 a genetic risk factor for Alzheimer's disease?Gallone S et al.. Dementia and geriatric cognitive disorders (2014)
- Effects of Paradoxical Sleep Deprivation on MCH and Hypocretin Systems.Agamme ALDA et al.. Sleep science (Sao Paulo, Brazil) (2024)
- Genetic determinants of daytime napping and effects on cardiometabolic health.Dashti HS et al.. Nat Commun (2021)
- Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake transition and hemodynamic stability during propofol, dexmedetomidine, and remifentanil anesthesia.Zheng Z et al.. Pharmacol Rep (2025)
- Contextual generalization of social stress learning is modulated by orexin receptors in basolateral amygdala.Yaeger JDW et al.. Neuropharmacology (2022)
- Pentylenetetrazol-induced seizures are exacerbated by sleep deprivation through orexin receptor-mediated hippocampal cell proliferation.Ni LY et al.. Neurol Sci (2014)
- CF-PA["Morishita R" et al.. Scientific reports (2019)
- T-Cell Mediation of Pregnancy Analgesia Affecting Chronic Pain in Mice.["Rosen S" et al.. The Journal of neuroscience : the official journal of the Society for Neuroscience (2017)
- PreImplantation factor (PIF*) promotes embryotrophic and neuroprotective decidual genes: effect negated by epidermal growth factor.Duzyj CM et al.. Journal of neurodevelopmental disorders (2014)
- Sleep interventions in AD trials show inconsistent cognitive benefits, possibly due to disease stage heterogeneitySleep Medicine Reviews (2021)
- Evaluation of the α-casein (CSN1S1) locus as a potential target for a site-specific transgene integration.["Smirnov A" et al.. Scientific reports (2022)
- Complexities of Understanding Function from CKD-Associated DNA Variants.["Lin J" et al.. Clinical journal of the American Society of Nephrology : CJASN (2020)
- Machine learning for clinical decision support in infectious diseases: a narrative review of current applications.["Peiffer-Smadja N" et al.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2020)
- Bioinformatic analysis of neuropeptide related genes in patients diagnosed with invasive breast carcinoma.Yay F et al.. Comput Biol Med (2024)
- PMID:37676320
- PMID:34052817
- PMID:31102663
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
2
Incoming
4202
Outgoing
2571
0 supporting
0 contradicting
2 neutral
🌍 Provenance Graph
9 nodes, 15 edges
derives from (14)
hypothesis-h-9e9fee95→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-9e9fee95analysis-SDA-2026-04-01-gap-v2→hypothesis-h-fb56c8a0hypothesis-h-fb56c8a0→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-82922df8
▸ Show 9 more
hypothesis-h-82922df8→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-3a901ec3hypothesis-h-3a901ec3→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-73e4340bhypothesis-h-73e4340b→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-0dea0ed5hypothesis-h-0dea0ed5→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-9eae33bahypothesis-h-9eae33ba→analysis-SDA-2026-04-01-gap-v2
supports (1)
🗣 Debate History2 sessions
gap_analysisWhat are the mechanisms underlying perivascular spaces and glymphatic clearance failure in ad?r4q=0.932026-04-01
gap_analysisWhat are the mechanisms underlying perivascular spaces and glymphatic clearance failure in ad?r4q=0.932026-04-01+0.000
This artifact has no version history yet.
Linked Artifacts (6767)
🧬 Related Hypotheses — same target / disease (20)
Chronotherapeutic Orexin Modulation for Tau Clearance
Score: 0.000 · Target: HCRTR1/HCRTR2 · —
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.924 · Target: NLRP3, CASP1, IL1B, PYCARD · neurodegeneration
APOE-Dependent Autophagy Restoration
Score: 0.895 · Target: MTOR · neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 · Target: SLC16A1, SLC16A7, LDHA, PDHA1 · neurodegeneration
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphoryla
Score: 0.895 · Target: MAPK14/PRMT1 · neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 · Target: SIRT1 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial
Score: 0.887 · Target: IFNG · neurodegeneration
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.886 · Target: TREM2-APOE axis · neurodegeneration
Complement Cascade Inhibition Synaptic Protection
Score: 0.867 · Target: — · neurodegeneration
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Tran
Score: 0.862 · Target: NAMPT · neurodegeneration
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State
Score: 0.856 · Target: EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B · neurodegeneration
Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 · Target: SMPD1 · neurodegeneration
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.844 · Target: TYROBP · neurodegeneration
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
Score: 0.844 · Target: SMPD3 · neurodegeneration
miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Mic
Score: 0.843 · Target: MIR155 · neurodegeneration
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome
Score: 0.839 · Target: SST, SSTR1, SSTR2 · neurodegeneration
Gamma Oscillation Enhancement Synergy
Score: 0.838 · Target: — · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-9e9fee95?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](http://scidex.ai/artifact/hypothesis-h-9e9fee95)
Direct URL
http://scidex.ai/artifact/hypothesis-h-9e9fee95
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.